302 related articles for article (PubMed ID: 27021607)
1. Efficacy and Safety of Belimumab Plus Standard Therapy in Patients With Systemic Lupus Erythematosus: A Meta-analysis.
Wei LQ; Liang YG; Zhao Y; Liang HT; Qin DC; She MC
Clin Ther; 2016 May; 38(5):1134-40. PubMed ID: 27021607
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of belimumab therapy in systemic lupus erythematosus: A systematic review and meta-analysis.
Chiang HY; Guo ZA; Wu TW; Peng TR
Lupus; 2022 May; 31(6):666-673. PubMed ID: 35321609
[TBL] [Abstract][Full Text] [Related]
5. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2018 Jan; 27(1):112-119. PubMed ID: 28592201
[TBL] [Abstract][Full Text] [Related]
7. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
[TBL] [Abstract][Full Text] [Related]
8. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Struemper H; Roth D
Mod Rheumatol; 2019 May; 29(3):452-460. PubMed ID: 29792370
[TBL] [Abstract][Full Text] [Related]
10. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
11. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
12. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
13. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
14. Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
van Vollenhoven RF; Petri M; Wallace DJ; Roth DA; Molta CT; Hammer AE; Tang Y; Thompson A
Arthritis Rheumatol; 2016 Sep; 68(9):2184-92. PubMed ID: 26992106
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.
Brunner HI; Abud-Mendoza C; Viola DO; Calvo Penades I; Levy D; Anton J; Calderon JE; Chasnyk VG; Ferrandiz MA; Keltsev V; Paz Gastanaga ME; Shishov M; Boteanu AL; Henrickson M; Bass D; Clark K; Hammer A; Ji BN; Nino A; Roth DA; Struemper H; Wang ML; Martini A; Lovell D; Ruperto N;
Ann Rheum Dis; 2020 Oct; 79(10):1340-1348. PubMed ID: 32699034
[TBL] [Abstract][Full Text] [Related]
16. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
[TBL] [Abstract][Full Text] [Related]
17. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
19. Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and meta-analysis of randomised controlled trials.
Xu Y; Xu JW; Wang YJ; Tung TH; Chien CW
Int Immunopharmacol; 2022 Aug; 109():108811. PubMed ID: 35512563
[TBL] [Abstract][Full Text] [Related]
20. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
